Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients
- PMID: 9303359
- PMCID: PMC2228019
- DOI: 10.1038/bjc.1997.433
Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients
Abstract
Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.
Comment in
-
Induction of cachexia in mice.Br J Cancer. 1999 Mar;79(9-10):1620-1. doi: 10.1038/sj.bjc.6690258. Br J Cancer. 1999. PMID: 10188916 Free PMC article. No abstract available.
Similar articles
-
Induction of muscle protein degradation by a tumour factor.Br J Cancer. 1997;76(8):1035-40. doi: 10.1038/bjc.1997.504. Br J Cancer. 1997. PMID: 9376263 Free PMC article.
-
Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice.Cancer Res. 1989 Jul 15;49(14):3800-4. Cancer Res. 1989. PMID: 2736521
-
Mechanism of muscle protein degradation in cancer cachexia.Br J Cancer. 1993 Aug;68(2):314-8. doi: 10.1038/bjc.1993.334. Br J Cancer. 1993. PMID: 8347486 Free PMC article.
-
New cachexic factors.Curr Opin Clin Nutr Metab Care. 1998 May;1(3):253-6. doi: 10.1097/00075197-199805000-00003. Curr Opin Clin Nutr Metab Care. 1998. PMID: 10565357 Review.
-
Pathogenesis of cancer cachexia.J Support Oncol. 2003 Sep-Oct;1(3):159-68. J Support Oncol. 2003. PMID: 15334872 Review.
Cited by
-
Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB.Br J Cancer. 2003 Sep 15;89(6):1116-22. doi: 10.1038/sj.bjc.6601132. Br J Cancer. 2003. PMID: 12966435 Free PMC article.
-
The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention.JCSM Clin Rep. 2018 Jul-Dec;3(2):e00065. JCSM Clin Rep. 2018. PMID: 31134216 Free PMC article.
-
Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines.Br J Cancer. 2008 Jul 8;99(1):126-32. doi: 10.1038/sj.bjc.6604458. Br J Cancer. 2008. PMID: 18594538 Free PMC article.
-
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.Br J Clin Pharmacol. 2000 May;49(5):485-8. doi: 10.1046/j.1365-2125.2000.00189.x. Br J Clin Pharmacol. 2000. PMID: 10792207 Free PMC article.
-
Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid.Br J Cancer. 1999 Jun;80(8):1231-5. doi: 10.1038/sj.bjc.6690490. Br J Cancer. 1999. PMID: 10376976 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources